Currently Enrolling Clinical Trials

Janssen’s Galaxi: A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease

  • Disease: Moderate/Severe Crohn’s Disease
  • Study Drug: Guselkumab vs Placebo vs Ustekinumab
  • Phase: II/III
  • Participation: Blinded induction and maintenance study, up to 156 weeks long